Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.
Part E—General Provisions Relating to Drugs and Devices
Part E—General Provisions Relating to Drugs and Devices is a U.S. Code division of Subchapter V—Drugs and Devices; in force.
https://ontology.bommaritollc.com/id/01a0f06c-cb9b-72d3-b67d-4d99ebbaa239
Elsewhere
Facts
| adms:identifier | |
| prov:wasDerivedFrom | |
| schema:isPartOf | |
| schema:legislationIdentifier | 21 U.S.C. Chapter 9, Subchapter V, Part E |
| schema:legislationJurisdiction | |
| schema:legislationLegalForce | |
| schema:legislationType | |
| skos:prefLabel | Part E—General Provisions Relating to Drugs and Devicesen |
Related
Parts (21)schema:isPartOf
- 21 U.S.C. 360bbb Expanded access to unapproved therapies and diagnostics
- 21 U.S.C. 360bbb-0 Expanded access policy required for investigational drugs
- 21 U.S.C. 360bbb-0a Investigational drugs for use by eligible patients
- 21 U.S.C. 360bbb-1 Dispute resolution
- 21 U.S.C. 360bbb-2 Classification of products
- 21 U.S.C. 360bbb-3 Authorization for medical products for use in emergencies
- 21 U.S.C. 360bbb-3a Emergency use of medical products
- 21 U.S.C. 360bbb-3b Products held for emergency use
- 21 U.S.C. 360bbb-3c Expedited development and review of medical products for emergency uses
- 21 U.S.C. 360bbb-4 Countermeasure development, review, and technical assistance
- 21 U.S.C. 360bbb-4a Priority review to encourage treatments for agents that present national security threats
- 21 U.S.C. 360bbb-4b Medical countermeasure master files
- 21 U.S.C. 360bbb-5 Critical Path Public-Private Partnerships
- 21 U.S.C. 360bbb-5a Emerging technology program
- 21 U.S.C. 360bbb-6 Risk communication
- 21 U.S.C. 360bbb-7 Notification
- 21 U.S.C. 360bbb-8 Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
- 21 U.S.C. 360bbb-8a Optimizing global clinical trials
- 21 U.S.C. 360bbb-8b Use of clinical investigation data from outside the United States
- 21 U.S.C. 360bbb-8c Patient participation in medical product discussion
- 21 U.S.C. 360bbb-8d Notification, nondistribution, and recall of controlled substances